You searched for: incas (Danska - Engelska)

disse data fra incas illustrerer at brugen af meget aktive stofbehandlinger er associeret med en forsinkning i udviklingen af antiretroviral stofresistens.
these data from incas illustrate that the use of highly active drug therapies is associated with a delay in the development of antiretroviral drug resistance.

genotypisk og fænotypisk resistens blev undersøgt hos patienter som modtog viramune i triple og dobbelt behandling i stofkombinationsbehandling, og i den ikke - viramune sammenligningsgruppe fra incas- studiet.
genotypic and phenotypic resistance was examined for patients receiving viramune in triple and double therapy drug combination therapy, and in the non-viramune comparative 39 group from the incas study.

et varigt respons i mindst 1 år blev dokumenteret i et forsøg (incas) for triple behandlingsarm med viramune, zidovudin og didanosin sammenlignet med zidovidin + didanosin eller viramune + zidovudin hos 151 hiv-1 smittede, hos naive patienter med cd4+ celletælling på 200-600 celler/mm3 (gennemsnitlig 376 celler/mm3) og gennemsnitlig udgangsværdi hiv-1 rna koncentration i plasma på 4, 41 log10 kopier/ml (25. 704 kopier/ml) .
a durable response for at least one year was documented in a trial (incas) for the triple therapy arm with viramune, zidovudine and didanosine compared to zidovudine + didanosine or viramune + zidovudine in 151 hiv-1 infected, treatment naive patients with cd4+ cell counts of 200-600 cells/mm3 (mean 376 cells/mm3) and a mean baseline plasma hiv-1 rna concentration of 4.41 log10 copies/ml (25,704 copies/ml) .treatment doses were viramune, 200 mg daily for two weeks,